SAREPTA THERAPEUTICS INC (SRPT) Stock News
NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD
SRPT Latest News, Press Relases and Analysis
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN)
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.
Monday's session: top gainers and losers
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Mentions: SLDB
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Cantor Fitzgerald upgraded Analog Devices (ADI) to Overweight from Neutral with a price target of $270, up from $250. Analog Devices is a “best-in-class” analog company, with “outsized” industrial exposure which is preferential into the upcycle, the firm tells investors in a research note. Argus upgrad
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
Mentions: SLDB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such...
Roku upgraded, Sarepta downgraded: Wall Street's top analyst calls
Roku upgraded, Sarepta downgraded: Wall Street's top analyst calls
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Chair Powell’s language regarding potential rate cuts later this year. Currently, markets are pricing in a roughly 56% chance of a quarter-point cut by September. In the background, rising tensions between Israel and Iran continue to cast a long shadow. Oil prices
Stock market today: Dow, S&P 500, Nasdaq jump, oil slides amid hopes Israel-Iran conflict stays contained
Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader regional crisis.
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Agenus Inc. (NASDAQ:AGEN) is among the 10 Most Undervalued Stocks to Buy for Under $5. Despite a 39% surge over the past month, it is still a bargain stock, considering its low forward price-earnings ratio. The company’s shares have soared on the back of notable recent developments. On June 3, Agenus Inc. (NASDAQ:AGEN) announced that […]
Stock market today: Dow, S&P 500, Nasdaq rebound, oil slips as Israel-Iran conflict enters 4th day
Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader regional crisis.
Top movers in Monday's session
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
These stocks are gapping in today's session
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Stock market today: Dow, S&P 500, Nasdaq rise, oil slips as Israel-Iran conflict enters 4th day
Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader regional crisis.
Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets
Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.
Monday's pre-market session: top gainers and losers
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.